Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...
Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...
Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Linfoma</strong> <strong>no</strong> <strong>Hodgkin</strong> <strong>en</strong> <strong>adultos</strong>: Tratami<strong>en</strong>to (<strong>PDQ®</strong>) - <strong>National</strong> Cancer Institute<br />
29. Williams CD, Harrison CN, Lister TA, et al.: High-dose therapy and autologous stem-cell support for<br />
chemos<strong>en</strong>sitive transformed low-grade follicular <strong>no</strong>n-<strong>Hodgkin</strong>'s lymphoma: a case-matched study from the<br />
European Bone Marrow Transplant Registry. J Clin Oncol 19 (3): 727-35, 2001. [PUBMED Abstract]<br />
30. Facon T, Brouillard M, Duhamel A, et al.: Prog<strong>no</strong>stic factors in Wald<strong>en</strong>ström's macroglobulinemia: a report<br />
of 167 cases. J Clin Oncol 11 (8): 1553-8, 1993. [PUBMED Abstract]<br />
31. Vijay A, Gertz MA: Wald<strong>en</strong>ström macroglobulinemia. Blood 109 (12): 5096-103, 2007. [PUBMED Abstract]<br />
32. Dimopoulos MA, Kyle RA, Anag<strong>no</strong>stopoulos A, et al.: Diag<strong>no</strong>sis and managem<strong>en</strong>t of Wald<strong>en</strong>strom's<br />
macroglobulinemia. J Clin Oncol 23 (7): 1564-77, 2005. [PUBMED Abstract]<br />
33. Leblond V, B<strong>en</strong>-Othman T, Deconinck E, et al.: Activity of fludarabine in previously treated<br />
Wald<strong>en</strong>ström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. J Clin<br />
Oncol 16 (6): 2060-4, 1998. [PUBMED Abstract]<br />
34. Foran JM, Rohatiner AZ, Coiffier B, et al.: Multic<strong>en</strong>ter phase II study of fludarabine phosphate for pati<strong>en</strong>ts<br />
with newly diag<strong>no</strong>sed lymphoplasmacytoid lymphoma, Wald<strong>en</strong>ström's macroglobulinemia, and mantle-cell<br />
lymphoma. J Clin Oncol 17 (2): 546-53, 1999. [PUBMED Abstract]<br />
35. Baldini L, Goldaniga M, Guffanti A, et al.: Immu<strong>no</strong>globulin M mo<strong>no</strong>clonal gammopathies of undetermined<br />
significance and indol<strong>en</strong>t Wald<strong>en</strong>strom's macroglobulinemia recognize the same determinants of evolution<br />
into symptomatic lymphoid disorders: proposal for a common prog<strong>no</strong>stic scoring system. J Clin Oncol 23<br />
(21): 4662-8, 2005. [PUBMED Abstract]<br />
36. Dhodapkar MV, Hoering A, Gertz MA, et al.: Long-term survival in Wald<strong>en</strong>strom macroglobulinemia: 10year<br />
follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113 (4): 793-6, 2009.<br />
[PUBMED Abstract]<br />
37. Gertz MA, Anag<strong>no</strong>stopoulos A, Anderson K, et al.: Treatm<strong>en</strong>t recomm<strong>en</strong>dations in Wald<strong>en</strong>strom's<br />
macroglobulinemia: cons<strong>en</strong>sus panel recomm<strong>en</strong>dations from the Second International Workshop on<br />
Wald<strong>en</strong>strom's Macroglobulinemia. Semin Oncol 30 (2): 121-6, 2003. [PUBMED Abstract]<br />
38. Dimopoulos MA, Anag<strong>no</strong>stopoulos A, Kyrtsonis MC, et al.: Primary treatm<strong>en</strong>t of Wald<strong>en</strong>ström<br />
macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25 (22): 3344-9,<br />
2007. [PUBMED Abstract]<br />
39. Treon SP, Branagan AR, Ioakimidis L, et al.: Long-term outcomes to fludarabine and rituximab in<br />
Wald<strong>en</strong>ström macroglobulinemia. Blood 113 (16): 3673-8, 2009. [PUBMED Abstract]<br />
40. Dimopoulos MA, Zervas C, Zomas A, et al.: Treatm<strong>en</strong>t of Wald<strong>en</strong>ström's macroglobulinemia with<br />
rituximab. J Clin Oncol 20 (9): 2327-33, 2002. [PUBMED Abstract]<br />
41. Treon SP, Branagan AR, Hunter Z, et al.: Paradoxical increases in serum IgM and viscosity levels<br />
following rituximab in Wald<strong>en</strong>strom's macroglobulinemia. Ann Oncol 15 (10): 1481-3, 2004. [PUBMED<br />
Abstract]<br />
42. Dimopoulos MA, Kantarjian H, Weber D, et al.: Primary therapy of Wald<strong>en</strong>ström's macroglobulinemia<br />
with 2-chlorodeoxyade<strong>no</strong>sine. J Clin Oncol 12 (12): 2694-8, 1994. [PUBMED Abstract]<br />
43. Dimopoulos MA, Alexanian R: Wald<strong>en</strong>strom's macroglobulinemia. Blood 83 (6): 1452-9, 1994. [PUBMED<br />
Abstract]<br />
44. Hellmann A, Lewandowski K, Zaucha JM, et al.: Effect of a 2-hour infusion of 2-chlorodeoxyade<strong>no</strong>sine in<br />
the treatm<strong>en</strong>t of refractory or previously untreated Wald<strong>en</strong>ström's macroglobulinemia. Eur J Haematol 63<br />
(1): 35-41, 1999. [PUBMED Abstract]<br />
45. García-Sanz R, Montoto S, Torrequebrada A, et al.: Wald<strong>en</strong>ström macroglobulinaemia: pres<strong>en</strong>ting features<br />
and outcome in a series with 217 cases. Br J Haematol 115 (3): 575-82, 2001. [PUBMED Abstract]<br />
46. Buske C, Hoster E, Dreyling M, et al.: The addition of rituximab to front-line therapy with CHOP (R-<br />
CHOP) results in a higher response rate and longer time to treatm<strong>en</strong>t failure in pati<strong>en</strong>ts with<br />
lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study<br />
Group (GLSG). Leukemia 23 (1): 153-61, 2009. [PUBMED Abstract]<br />
47. Ghobrial IM, Hong F, Padmanabhan S, et al.: Phase II trial of weekly bortezomib in combination with<br />
rituximab in relapsed or relapsed and refractory Wald<strong>en</strong>strom macroglobulinemia. J Clin Oncol 28 (8):<br />
1422-8, 2010. [PUBMED Abstract]<br />
file:///Users/mauriciolema/Docum<strong>en</strong>ts/MLMGuias_09_<strong>Linfoma</strong>No<strong>Hodgkin</strong>.webarchive<br />
29/09/11 6:15<br />
Página 15 de 61
Change language